Drug Profile
ATI 1701
Alternative Names: ATI-1701Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator National Research Council Canada
- Developer Appili Therapeutics; National Research Council Canada
- Class Anti-infectives; Attenuated vaccines; Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tularaemia
Most Recent Events
- 15 Feb 2024 ATI 1701 is still in preclinical studies for Tularaemia in Canada
- 13 Feb 2024 Appili Therapeutics expects to receive feedback on pre-IND meeting with FDA in early 2024
- 28 Dec 2023 No recent reports of development identified for preclinical development in Tularaemia(Prevention) in Canada (Parenteral)